Payment overview · 2025
General Payments
$1,763.54
94 reported records · 23 companies
Healthcare provider profile · identity verified
Mark A Cline, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · NACOGDOCHES, TX · NPI 1477563898
Verified facts
What the public records show
CMS Open Payments records show Mark A Cline, M.D. received $1,763.54 in general payments during 2025 across 94 reported records.
Novo Nordisk Inc accounted for 15.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexium by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $274.22 | 15.6% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $247.26 | 14.0% | 10 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $188.62 | 10.7% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $165.90 | 9.4% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $148.45 | 8.4% | 14 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $96.83 | 5.5% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $92.31 | 5.2% | 6 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $83.32 | 4.7% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $62.19 | 3.5% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.51 | 3.0% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $51.80 | 2.9% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $37.88 | 2.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $33.39 | 1.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.29 | 1.9% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $31.30 | 1.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $29.38 | 1.7% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $23.98 | 1.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $23.18 | 1.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.89 | 1.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.95 | 1.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.61 | 0.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.23 | 0.9% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.05 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,763.54 | 94 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $211.18 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $188.62 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $162.45 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $153.78 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $151.81 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $151.81 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $101.13 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $96.83 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $92.31 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $80.97 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $75.97 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $69.24 | 6 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $67.48 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $63.04 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $62.19 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $52.51 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $52.51 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $51.80 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $43.18 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $37.88 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $33.39 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $33.29 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $29.38 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $24.45 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $23.98 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $23.18 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.95 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $20.95 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.95 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.23 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.09 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 167 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 145 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 78 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 63 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 150 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 31 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | 17 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
145 | 50 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
78 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
31 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
78 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
63 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
150 | 62 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
167 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 929 | 164 |
| Alprazolam | Alprazolam | 584 | 130 |
| Tramadol Hcl | Tramadol Hcl | 542 | 154 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 477 | 194 |
| Levothyroxine Sodium | Levothyroxine Sodium | 406 | 191 |
| Atorvastatin Calcium | Atorvastatin Calcium | 396 | 189 |
| Amlodipine Besylate | Amlodipine Besylate | 381 | 166 |
| Pantoprazole Sodium | Pantoprazole Sodium | 346 | 150 |
| Lisinopril | Lisinopril | 335 | 156 |
| Gabapentin | Gabapentin | 308 | 155 |
| Losartan Potassium | Losartan Potassium | 279 | 130 |
| Metoprolol Succinate | Metoprolol Succinate | 254 | 117 |
| Pregabalin | Pregabalin | 246 | 74 |
| Omeprazole | Omeprazole | 219 | 103 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 98 |
| Metformin Hcl | Metformin Hcl | 191 | 80 |
| Clonazepam | Clonazepam | 190 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 187 | 53 |
| Simvastatin | Simvastatin | 182 | 72 |
| Eliquis | Apixaban | 167 | 45 |
| Meloxicam | Meloxicam | 160 | 70 |
| Montelukast Sodium | Montelukast Sodium | 158 | 72 |
| Sertraline Hcl | Sertraline Hcl | 156 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 64 |
| Ozempic | Semaglutide | 150 | 62 |
| Farxiga | Dapagliflozin Propanediol | 145 | 50 |
| Azithromycin | Azithromycin | 126 | 122 |
| Clopidogrel | Clopidogrel Bisulfate | 120 | 54 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 116 | 43 |
| Furosemide | Furosemide | 113 | 51 |
| Trazodone Hcl | Trazodone Hcl | 107 | 48 |
| Testosterone Cypionate | Testosterone Cypionate | 106 | 35 |
| Allopurinol | Allopurinol | 102 | 33 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 100 | 16 |
| Potassium Chloride | Potassium Chloride | 93 | 46 |
| Carvedilol | Carvedilol | 87 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 43 |
| Metformin Hcl Er | Metformin Hcl | 81 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 39 |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | 25 |
| Jardiance | Empagliflozin | 78 | 33 |
| Finasteride | Finasteride | 70 | 34 |
| Prednisone | Prednisone | 67 | 51 |
| Temazepam | Temazepam | 67 | 22 |
| Aripiprazole | Aripiprazole | 66 | 26 |
| Mounjaro | Tirzepatide | 63 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 25 |
| Donepezil Hcl | Donepezil Hcl | 56 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 27 |
| Diazepam | Diazepam | 54 | 13 |
| Lorazepam | Lorazepam | 54 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 28 |
| Celecoxib | Celecoxib | 53 | 29 |
| Nifedipine Er | Nifedipine | 52 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 50 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 23 |
| Famotidine | Famotidine | 47 | 23 |
| Trulicity | Dulaglutide | 47 | 13 |
| Eszopiclone | Eszopiclone | 45 | 11 |
| Buspirone Hcl | Buspirone Hcl | 44 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 21 |
| Memantine Hcl | Memantine Hcl | 43 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 20 |
| Xarelto | Rivaroxaban | 42 | 17 |
| Atenolol | Atenolol | 40 | 15 |
| Cephalexin | Cephalexin | 40 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 26 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | 17 |
| Glimepiride | Glimepiride | 38 | 18 |
| Spironolactone | Spironolactone | 38 | 19 |
| Benazepril Hcl | Benazepril Hcl | 37 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | 13 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 34 | suppressed |
| Ezetimibe | Ezetimibe | 34 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 17 |
| Bupropion Xl | Bupropion Hcl | 33 | 17 |
| Epinephrine | Epinephrine | 33 | 31 |
| Mirtazapine | Mirtazapine | 33 | 16 |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | 17 |
| Alendronate Sodium | Alendronate Sodium | 31 | 15 |
| Estradiol | Estradiol | 31 | 20 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 31 | 27 |
| Valacyclovir | Valacyclovir Hcl | 31 | 15 |
| Alprazolam Xr | Alprazolam | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 13 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 17 |
| Ondansetron Odt | Ondansetron | 28 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Primidone | Primidone | 28 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 22 |
| Veo Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 27 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | 14 |
| Levofloxacin | Levofloxacin | 26 | 25 |
| Modafinil | Modafinil | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | 13 |
| Sucralfate | Sucralfate | 25 | suppressed |
| Baclofen | Baclofen | 24 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 24 | 15 |
| Progesterone | Progesterone, Micronized | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 20 |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | 11 |
| Valsartan | Valsartan | 23 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 15 |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | 13 |
| Glipizide | Glipizide | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 19 |
| Meclizine Hcl | Meclizine Hcl | 20 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 19 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 14 |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 14 |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | 12 |
| Linzess | Linaclotide | 17 | 11 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | 12 |
| Topiramate | Topiramate | 16 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | 15 |
| Digoxin | Digoxin | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 12 |
| Belsomra | Suvorexant | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,763.54 · 94 records | Novo Nordisk Inc | AIRSUPRA, AUSTEDO XR, Auvelity, Azstarys, BREZTRI, CAPVAXIVE, Dexcom G6 Transmitter, ELIQUIS, ENFLONSIA, EVENITY, FARXIGA, Flucelvax, GARDASIL 9, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, Sunosi, Symbravo, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, Wegovy, XIFAXAN, XYOSTED, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error